Diplomatic Trade Ltd, a global trade and investment platform, has finalized a transformative cross-border investment in the Turkish pharmaceutical manufacturer Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S., marking a strategic expansion in the Middle Eastern and North African (MENA) healthcare sector.
The investment, facilitated through Diplomatic Trade Capital Group, involves acquiring a 49% controlling equity stake in the Turkish pharmaceutical conglomerate. This substantial transaction positions the company to develop advanced pharmaceutical infrastructure and potentially launch a significant initial public offering (IPO) by the fourth quarter of 2025.
A key component of this strategic partnership is the planned development of a cutting-edge bio-manufacturing facility in the United Arab Emirates, scheduled for launch in the third quarter of 2025. The facility will specialize in biosynthetic therapies, regenerative compounds, and advanced life-extension pharmaceuticals, targeting growing healthcare demands across Gulf states and North Africa.
The proposed manufacturing site will integrate sophisticated technologies, including AI-driven quality control, biocompatible packaging, and modular production suites compliant with European Union Good Manufacturing Practice (EU-GMP) standards. This approach underscores the partnership’s commitment to innovation and regulatory excellence in pharmaceutical development.
Institutional backing for the transaction comes from Morgan Brookshire LLC, a U.S.-based private family office, which has structured the underlying financing. This investment represents a significant transatlantic collaboration in developing critical pharmaceutical infrastructure and aligns with broader economic cooperation between the United States and Gulf Cooperation Council (GCC) regions.
Early financial projections suggest the newly formed group could achieve an IPO valuation approaching $300 million, supported by robust earnings before interest, taxes, depreciation, and amortization (EBITDA) expansion, comprehensive GCC distribution rights, and a promising portfolio of proprietary therapeutic compounds.
The strategic partnership aims to enhance pharmaceutical sovereignty and improve healthcare access in the MENA region. By combining the Turkish company’s extensive manufacturing expertise with Diplomatic Trade’s investment capabilities, the collaboration represents a significant step toward developing innovative, regionally focused healthcare solutions.
This news story relied on a press release distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Diplomatic Trade Ltd Acquires Major Stake in Turkish Pharmaceutical Firm, Targets $300M IPO.